Cutting edge oncology research progresses more quickly than anticipated
Redx Pharma reaches pre-clinical proof of concept stage with oncology lead Chronic Lymphocytic Leukaemia (CLL) patients commonly develop resistance to gold-standard?therapy (the?irreversible Bruton’s Tyrosine Kinase [BTK] inhibitor,?ibrutinib)?due to a?genetic mutation. ? Redx’s new candidate is?a reversible BTK inhibitor and could target?resistant CLL?and other blood cancers. Could be a significant step in the potential advancement of[…]